Published in Health Business Week, May 27th, 2005
For the 3 months ended March 31, 2005, revenue increased 21.4% to a record $32,335,000 from $26,633,000 for the first quarter of 2004. Sales of neuro products increased 18.5% to $28,717,000 for this year's first quarter compared to $24,228,000 a year earlier, as sales of ANS' Genesis and GenesisXP implantable spinal cord stimulation (SCS) systems for the treatment of chronic pain continued to perform well in the marketplace.
Gross margin was 74% for both...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.